Press Release

13 November 2023

Get ready for the end-of-year sale! Discover the future of drug discovery with OpenDEL™ and save 20% off!
27 October 2023

Infographic | HitGen FY2023 Q3 Report
19 October 2023

Venture forces invest millions in new type of treatment for particularly aggressive form of cancer

A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures has just made an investment in the Danish biotech company Dania Therapeutics (Dania Tx).
28 September 2023

SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, September 28, 2023 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a partnership with The Structural Genomics Consortium ("SGC"), a public-private partnership that supports the discovery of new medicines through open-access research. HitGen will utilize its DNA-encoded library (DEL) technology platform, specifically OpenDEL™, to screen under-represented targets chosen by SGC.
26 September 2023

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology

CASTRES, France and CAMBRIDGE, England, Sept. 25, 2023 – Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets.
22 August 2023

Infographic | HitGen FY2023 Half-Year Report
10 August 2023

HitGen Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics

CHENGDU, China, August 10, 2023 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research service agreement with Nested Therapeutics, Inc. ("Nested"), a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, under which HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify hits against targets of interest to Nested.
26 June 2023

HitGen launches a newly upgraded version of OpenDEL™, a self-service screening kit, to facilitate innovative drug discovery research

CHENGDU, China, June 26, 2023 – HitGen Inc. ("HitGen", SSE: 688222.SH) has recently launched a newly upgraded version of its OpenDEL™ product, a self-service screening kit for novel molecules.
18 May 2023

HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics

CHENGDU, China, May 18, 2023 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) announced today that it has entered into a research agreement with ARase Therapeutics, Inc. ("ARase"), a biotechnology company developing first-in-class therapeutics targeting ADP-ribose hydrolases, novel targets that function in therapeutically proven cancer stress pathways. HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify novel inhibitors of ARase’s validated oncology targets. HitGen will also support ARase programs from hit-to-lead chemistry to pre-clinical development.
28 April 2023

Infographic | HitGen FY2022 Annual Report

Infographic | HitGen FY2022 Annual Report

News

Press Release

Thanks for reading!